Business
Ford plant Cologne
(Oliver Berg/Getty Images)

Ford slips as tariffs take an $800 million bite out of its earnings

Ford announced its second-quarter earnings results after the bell on Wednesday.

Despite being more shielded from tariffs than many of its rivals, with 82% of its North American vehicles built in the US, Ford says levies have cost it $800 million so far this year.

The Detroit automaker detailed the tariff-related impact in its second-quarter earnings report, released after the market closed on Wednesday. Though Ford’s seen benefits from tariff panic buying and its four-month-long employee pricing discounts, the charges are still a hit to profits. Earlier this year, Ford estimated a $1.5 billion full-year tariff impact for 2025.

On Wednesday, it upwardly revised that to “about $2 billion.”

Ford posted adjusted earnings of $0.37 per share, beating the $0.33 per share analysts polled by FactSet expected. The automaker reported a net loss of $36 million on the quarter related to one-time charges (largely attributed to the cancellation of an electric SUV). Wall Streeted expected a $1.25 billion profit.

Ford’s shares were down about 2% in after-hours trading.

Sales came in at $50.2 billion, nearly 10% better than the $45.79 billion analysts were anticipating and up 5% from last year. Earlier this month, Ford said its second-quarter unit sales had risen 14% compared to last year.

Looking ahead, Ford expects full-year earnings before interest and taxes of between $6.5 billion and $7.5 billion. The automaker previously pulled its annual outlook amid tariff uncertainty. In February, Ford had projected full-year earnings before interest and taxes of between $7 billion and $8.5 billion, though those figures did not account for sector tariffs on vehicles or auto parts.

The automaker has been issuing recalls at a level bordering on legendary this year. Through June alone, Ford issued 88 safety recalls, more than the full-year total for any other automaker, ever.

Ford’s EV losses continued to pile up, with its Model e segment losing $1.33 billion on the quarter, 15% more than last year. The division has lost $2.18 billion through the first half of this year.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.